Loading...
XHKG
2172
Market cap1.12bUSD
Aug 08, Last price  
15.03HKD
1D
-3.47%
1Q
44.80%
IPO
-38.65%
Name

MicroPort NeuroTech Ltd

Chart & Performance

D1W1MN
No data to show
P/E
31.64
P/S
10.56
EPS
0.43
Div Yield, %
1.26%
Shrs. gr., 5y
-0.12%
Rev. gr., 5y
32.90%
Revenues
762m
+14.44%
183,720,000221,923,000382,799,000547,350,000665,624,000761,762,000
Net income
254m
+74.63%
46,975,00045,287,00024,170,000-21,765,000145,548,000254,165,000
CFO
0k
-100.00%
56,650,00047,234,000157,406,000223,798,000153,778,0000
Dividend
Jul 02, 20250.11 HKD/sh
Earnings
Aug 28, 2025

Profile

MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.
IPO date
Jul 15, 2022
Employees
575
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
761,762
14.44%
665,624
21.61%
547,350
42.99%
Cost of revenue
490,621
485,837
432,075
Unusual Expense (Income)
NOPBT
271,141
179,787
115,275
NOPBT Margin
35.59%
27.01%
21.06%
Operating Taxes
53,878
27,470
20,352
Tax Rate
19.87%
15.28%
17.66%
NOPAT
217,263
152,317
94,923
Net income
254,165
74.63%
145,548
-768.73%
(21,765)
-190.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
22,359
23,786
24,725
Long-term debt
51,885
98,934
145,763
Deferred revenue
19,136
Other long-term liabilities
59,400
35,567
7,894
Net debt
(1,088,189)
(985,651)
(812,942)
Cash flow
Cash from operating activities
153,778
223,798
CAPEX
(202,603)
(47,945)
Cash from investing activities
(233,159)
(344,523)
Cash from financing activities
(33,276)
329,537
FCF
169,918
322,082
(45,753)
Balance
Cash
1,014,401
1,084,358
1,134,703
Long term investments
148,032
24,013
(151,273)
Excess cash
1,124,345
1,075,090
956,062
Stockholders' equity
1,706,835
260,460
107,860
Invested Capital
679,012
1,474,718
1,471,597
ROIC
20.18%
10.34%
13.34%
ROCE
15.04%
10.36%
7.30%
EV
Common stock shares outstanding
579,057
582,658
517,543
Price
8.61
-29.66%
12.24
-46.67%
22.95
 
Market cap
4,985,681
-30.09%
7,131,734
-39.96%
11,877,612
 
EV
3,893,764
6,148,829
11,077,518
EBITDA
271,141
235,879
171,976
EV/EBITDA
14.36
26.07
64.41
Interest
3,460
99,277
Interest/NOPBT
1.92%
86.12%